Lupus最新文献

{"title":"Male infertility in lupus nephritis: Clinical implications and management strategies.","authors":"Tabassum Elahi, Saima Ahmed, Muhammed Mubarak","doi":"10.1177/09612033261454513","DOIUrl":"10.1177/09612033261454513","url":null,"abstract":"<p><p>Lupus nephritis, a severe manifestation of systemic lupus erythematosus, is a major contributor to morbidity and has significant implications for male reproductive health. Infertility in men with LN is multifactorial, resulting from disease-related immune dysregulation, renal impairment, gonadotoxic therapies such as cyclophosphamide, and the psychosocial burdens of chronic illness. Collectively, these factors impair spermatogenesis, disrupt the hypothalamic-pituitary-gonadal axis, and contribute to erectile dysfunction, diminished libido, hormonal disturbances, and abnormal semen parameters. This underscores the need to recognize male fertility as a critical yet often overlooked dimension of LN management.Encouragingly, fertility preservation strategies and assisted reproductive technologies (ART) provide viable pathways to parenthood. Sperm cryopreservation remains the most reliable and widely accessible option, while surgical sperm retrieval and experimental approaches, including testicular tissue cryopreservation and spermatogonial stem cell transplantation, are under active investigation. ART techniques such as intrauterine insemination (IUI) and in vitro fertilization with intracytoplasmic sperm injection (IVF-ICSI) have enabled conception even in severe cases, although disease quiescence is recommended prior to initiation to optimize outcomes. Notably, paternal exposure to most immunosuppressive agents rarely increases fetal teratogenic risk; however, agents like cyclophosphamide may impair male fertility, a separate gonadotoxic concern. Emerging biologic therapies, including rituximab and belimumab, show promise in LN management with potentially reduced reproductive toxicity, but further studies are needed to establish their safety in male fertility.This review highlights the clinical implications of male infertility in LN and emphasizes the importance of integrated management strategies that combine reproductive counseling, fertility-preserving interventions, and multidisciplinary care.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"1003-1012"},"PeriodicalIF":1.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147981998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum RIPK3/MLKL as exploratory biomarker candidates for systemic lupus erythematosus.","authors":"Guowang Zhao, Mingjun Li, Jianghong Lin, Qintong Xiao, Liu Wang, Qi Huang, Man Xiong, Yuanyuan Yang, Xiangming Yi","doi":"10.1177/09612033261465072","DOIUrl":"10.1177/09612033261465072","url":null,"abstract":"<p><p>ObjectiveThis study aims to elucidate the novel role of serum receptor interacting protein kinase 3 (RIPK3)/mixed series of protein kinase-like domains (MLKL) levels in SLE and assess their correlation with clinical manifestations and serological parameters.MethodsWe employed enzyme-linked immune sorbent assay (ELISA) analysis to evaluate RIPK3/MLKL protein levels in serum from 90 SLE patients and 50 healthy controls (HC).ResultsOur findings reveal a significant elevation of serum RIPK3/MLKL protein levels in SLE patients compared to HC (<i>p</i> = 0.0004 and <i>p</i> = 0.0005, respectively). Notably, these levels were closely associated with the disease's clinical manifestations, notably heightened in active SLE compared to stable cases (<i>p</i> = 0.0312 and <i>p</i> = 0.0096, respectively). Furthermore, while RIPK3 protein exhibited significant upregulation in patients with lupus nephritis (LN) compared to non-LN individuals (<i>p</i> = 0.0017). SLE patients with high anti-nuclear antibody (ANA) titers exhibited notably higher RIPK3 levels compared to those with low ANA titers (<i>p</i> < 0.0001). The receiver operating characteristic (ROC) curve demonstrated diagnostic potential for serum RIPK3/MLKL, with respective areas under the curve (AUCs) of 0.6319 (<i>p</i> = 0.0099) and 0.7374 (<i>p</i> < 0.0001).ConclusionsOur study illuminate serum RIPK3/MLKL proteins are exploratory biomarker candidates for SLE and necroptosis may be involved in SLE pathogenesis.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"1082-1089"},"PeriodicalIF":1.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148308712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment strategies and clinical outcomes in shrinking lung syndrome in systemic lupus erythematosus: An updated systematic review.","authors":"Júlia Ribeiro Lemos, Agnaldo José Lopes, Patrícia Dos Santos Vigário","doi":"10.1177/09612033261461973","DOIUrl":"10.1177/09612033261461973","url":null,"abstract":"<p><p>BackgroundShrinking lung syndrome (SLS) is a rare manifestation of systemic lupus erythematosus (SLE) lacking standardized management. This systematic review summarizes the current evidence on therapeutic interventions and clinical outcomes.MethodsFollowing PRISMA guidelines, we searched six databases (e.g., PubMed, Scopus, and Web of Science) for studies on adult SLS patients published up to January 2026. Methodological quality was assessed using JBI tools.ResultsForty studies (111 patients) were included (30 case reports and 10 case series); 87.5% presented a low risk of bias. There was a marked female predominance (91%), with a mean age of 33.5 ± 9.8 years. All patients showed a restrictive pattern (forced vital capacity: 47-52%). Glucocorticoids were the mainstay of therapy (95-96%). Rituximab emerged as an effective primary biologic for refractory cases. Non-pharmacological interventions, such as inspiratory muscle training and non-invasive ventilation, improved diaphragmatic strength. Although symptomatic resolution occurred in 75-95% of patients, complete functional recovery (normalization of pulmonary function tests) was achieved in only 20-23% of patients. Mortality directly attributed to SLS was low (2-5.5%).ConclusionsEarly glucocorticoid therapy remains essential, but complete functional recovery is rare, with 80% of patients maintaining chronic restriction. For refractory cases, multidisciplinary care integrating rituximab and respiratory rehabilitation should be considered to optimize functional outcomes.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"1040-1047"},"PeriodicalIF":1.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148258445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative performance of lupus disease-activity indices during pregnancy to predict adverse obstetric outcomes: A colombian SLE cohort.","authors":"Jairo Cajamarca-Barón, Catalina Sanmiguel-Reyes, Juan Esteban Bedoya-Loaiza, Claudia Ibáñez, Alejandro Escobar, Diana Guavita, Adriana Rojas-Villarraga","doi":"10.1177/09612033261458578","DOIUrl":"10.1177/09612033261458578","url":null,"abstract":"<p><p>ObjectiveTo compare the performance of five lupus disease-activity indices measured at a single retrospective pregnancy timepoint for discriminating a composite adverse obstetric outcome (AO), and to perform exploratory clinically interpretable categorical and renal-item analyses across indices.MethodsRetrospective cohort at a tertiary center in Bogotá, Colombia (2012-2024). For each pregnancy, one retrospective assessment with complete clinical and laboratory information required to compute all indices was selected. AO was defined as any of: preterm birth, miscarriage, stillbirth/early fetal death, preeclampsia/eclampsia, premature rupture of membranes, postpartum hemorrhage, thromboembolism, placental abruption, or maternal death. We calculated SLEPDAI, Lupus Activity Index in Pregnancy (LAI-P), modified SLAM (m-SLAM), SLE Disease Activity Score (SLE-DAS), and BILAG2004-P. Because the dataset was retrospective and selected on complete data, we treated categorical and renal-item analyses as exploratory.ResultsTwenty-nine pregnancies (28 women) were included; AO occurred in 18/29 (62.1%). The original continuous-score analyses showed overlapping confidence intervals across indices. Exploratory clinically interpretable analyses showed AO in 15/18 (83.3%) pregnancies with any BILAG2004-P A/B domain, 16/20 (80.0%) with SLEPDAI ≥3, and 13/14 (92.9%) with SLE-DAS >7.64. Exploratory renal analyses showed the clearest signals for BILAG2004-P renal A/B (13/14 vs 5/15; OR 26.0, 95% CI 2.61-259.31), SLEPDAI renal-item score >0 (13/13 vs 5/16; OR 56.45, 95% CI 2.81-1133.97), and the LAI-P renal item >0 (12/13 vs 6/16; OR 20.00, 95% CI 2.05-195.01).ConclusionIn this small single-center cohort, active lupus was associated with adverse obstetric outcomes across disease-activity instruments. However, the study is underpowered to detect meaningful differences in discrimination between indices. Renal activity remained the most clinically relevant organ-specific signal in exploratory analyses, but these findings should be interpreted cautiously and confirmed in larger longitudinal cohorts.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"1013-1018"},"PeriodicalIF":1.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148217360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Giant cell myocarditis in an 18-year-old patient with new-onset systemic lupus erythematosus: A fatal case of rapidly progressing heart failure.","authors":"Lisa C Harling, Max Wacker, Arjang Ruhparwar, Alexander Schmeisser, Jens Wippermann","doi":"10.1177/09612033261465053","DOIUrl":"10.1177/09612033261465053","url":null,"abstract":"<p><p><b>Background:</b> Giant cell myocarditis (GCM) is a rare, and often fatal subtype of myocarditis, with limited reports of association with systemic lupus erythematosus (SLE). <b>Purpose:</b> We are first to report a unique case of an 18-year-old patient presenting with biventricular heart failure and newly-onset SLE, ultimately diagnosed with GCM. <b>Analysis/Results:</b> The patient had a 6-month prodrome of fatigue, fever, and malaise, followed by acute decompensation. Echocardiography showed a severely reduced left ventricular ejection fraction (5%). Serology confirmed SLE, endomyocardial biopsy identified multinucleated giant cells, confirming GCM. Despite immediate initiation of extracorporeal membrane oxygenation (ECMO) and aggressive immunosuppressive therapy (methylprednisolone, antithymocyte globulin, cyclosporine), cardiac function did not recover. The patient received a biventricular assist device (BiVAD) as intermediate-term bridge-to-transplant. However, significant complications occurred in the form of multiorgan failure, thromboembolism, and hemodynamic deterioration, ultimately leading to death before transplantation was possible. <b>Conclusions:</b> This case underscores the importance of differentiating lupus myocarditis from GCM, given the dramatically different prognosis and treatment strategies. Early differential diagnosis via biopsy is essential, particularly in young patients with rapidly progressing cardiac decline and concurrent autoimmune serologies. Aggressive immunosuppression remains the cornerstone of treatment, attempting to reduce myocardial damage and the resulting need for transplantation. Clinicians should maintain suspicion of GCM in lupus patients with cardiac compromise to initiate timely interventions.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"1090-1098"},"PeriodicalIF":1.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13424903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148376317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal observation of thrombotic events in patients with obstetric antiphospholipid syndrome.","authors":"Yuta Inoue, Hiroyuki Nakamura, Yuichiro Fujieda, Mitsutaka Yasuda, Kohei Karino, Ryo Hisada, Michihito Kono, Olga Amengual, Tatsuya Atsumi","doi":"10.1177/09612033261464227","DOIUrl":"10.1177/09612033261464227","url":null,"abstract":"<p><p>ObjectiveWe aimed to investigate the long-term thrombotic outcomes in patients with obstetric antiphospholipid syndrome (OAPS) who initially presented without thrombosis and to identify clinical features associated with late thrombotic events.MethodsFemale patients with antiphospholipid syndrome (APS) and obstetric manifestations diagnosed at Hokkaido University Hospital between 2004 and 2024 were retrospectively analyzed. Patients were first compared cross-sectionally according to the presence or absence of a history of thrombosis at diagnosis. Among those without prior thrombosis, individuals were further analyzed in a nested case-control study comparing patients who developed new thrombotic events with those who remained event-free for more than 10 years.ResultsOf 47 female APS patients complicated with obstetric manifestations, 23 had a history of thrombosis but not in 24 patients. The prevalence of SLE was higher in the thrombotic group (74%) compared with 40% in the non-thrombotic group (p = 0.019, Fisher's exact test). During long-term follow-up, 4 of the 24 patients in the absence of prior thrombosis developed a first thrombotic event median of 16 years after the diagnosis. Of the remaining 20 OAPS patients, 9 patients who were observed for more than 10 years without any thrombotic events served as the control group and 11 patents with less than 10 years of follow-up were excluded. The presence of triple antiphospholipid antibodies (aPLs) and accumulation of conventional thrombotic risk factors were more frequent among the cases than the controls.ConclusionThrombotic events may occur in OAPS patients even decades after diagnosis of OAPS, particularly in those with high-risk aPL profiles and conventional thrombotic risk factors. These findings underscore the importance of long-term vigilance and individualized prevention strategies in OAPS management.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"1075-1081"},"PeriodicalIF":1.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148302093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of systemic lupus erythematosus with 90-day readmission following heart failure hospitalization: A national readmission database (NRD) analysis, 2016-2017.","authors":"Farheen Malik, Muhammad Saad, Minahil Javaid, Fatima Gul, Meerub Fatima Zafar, Rai Muhammad Umar Khan, Syed Nosherwan Ali, Rija Tahir, Ishba Manal, Saba Fatima, Sunny Kumar, Komal Saleem, Komal Kumari, Jawad Ahmed","doi":"10.1177/09612033261465925","DOIUrl":"10.1177/09612033261465925","url":null,"abstract":"<p><p>BackgroundSystemic lupus erythematosus is a chronic autoimmune disease associated with heightened cardiovascular risk. Data on the impact of systemic lupus erythematosus on outcomes following heart failure hospitalization remain limited. This study aimed to evaluate whether systemic lupus erythematosus is independently associated with 90-days readmission and other clinical outcomes among patients hospitalized with heart failure.MethodsWe conducted a retrospective cohort study using the 2016-2017 Nationwide Readmissions Database to evaluate the association of systemic lupus erythematosus with 90-days readmission after heart failure hospitalization. Adults ≥18 years with an index admission for heart failure were included. The primary outcome was 90-days all-cause readmission. Secondary outcomes included in-hospital mortality, median length of stay, and hospitalization costs. Multivariable Cox proportional hazards were used to identify independent predictors of outcomes.ResultsAmong 1,625,731 patients hospitalized with heart failure, 9096 had comorbid systemic lupus erythematosus. Compared with non-systemic lupus erythematosus patients, those with systemic lupus erythematosus were younger (mean age 61 vs 72 years), predominantly female, and more likely to have socioeconomic disadvantage and a higher comorbidity burden. The 90-days readmission rate was significantly higher in the systemic lupus erythematosus cohort (41%) versus the non-systemic lupus erythematosus cohort (34%) (HR: 1.07; 95% CI: 1.02-1.12; <i>p</i> = 0.010). In-hospital mortality did not differ significantly between groups; however, mortality during readmissions was nearly doubled compared with index admissions (5.4% vs 2.9%). SLE patients had a median length of stay of 4 days (vs 4 days in non-SLE) and incurred median hospitalization costs of USD 32,872 (13% higher than non-SLE patients). Independent predictors of readmission included Medicaid insurance, weekend admission, renal failure, myocardial infarction, and discharge to a non-home setting, whereas female sex, treatment at metropolitan teaching hospitals, and comorbid hypertension or diabetes were associated with a lower risk of readmission.ConclusionSystemic lupus erythematosus is independently associated with an increased risk of 90-days readmission following heart failure hospitalization, contributing to greater healthcare utilization and costs. These findings highlight the need for tailored strategies for transitional care, multidisciplinary follow-up, and socioeconomic support.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"1066-1074"},"PeriodicalIF":1.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148382325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling the role of TLR9 promoter variants in susceptibility and clinical features of systemic lupus erythematosus.","authors":"Fatemeh Soleimani, Hamidreza Karbalaei-Musa, Mohammad Hossein Hajali, Taiebe Kenarangi, Meysam Mosallaei, Narges Ansari","doi":"10.1177/09612033261458560","DOIUrl":"10.1177/09612033261458560","url":null,"abstract":"<p><p>ObjectiveSystemic lupus erythematosus (SLE) is a multifactorial autoimmune disease in which dysregulated nucleic acid sensing and type I interferon responses drive autoantibody production and organ damage. Toll-like receptor 9 (TLR9) regulates these pathways, and promoter variants (rs187084 and rs5743836) may alter TLR9 expression and modulate disease susceptibility and severity. This study evaluated the association of these promoter SNPs and their haplotypes with SLE risk and clinical/laboratory features in an Iranian population.MethodsIn this case-control study, we genotyped TLR9 promoter SNPs rs187084 and rs5743836 in 140 SLE patients and 140 age- and sex-matched healthy controls using the real-time PCR-high resolution melting (PCR-HRM) assay.ResultsOur analysis showed that the CC and CT genotypes and the C allele of the rs5743836 SNP were associated with an increased risk of SLE (P < 0.05). However, there was no association between the rs187084 SNP and the risk of SLE (P > 0.05). The combined rs187084-rs5743836 CC haplotype was associated with increased SLE risk (CC vs TT haplotype, P < 0.001). Furthermore, in the patient group, carriers of the C allele in both promoter variants exhibited earlier disease onset and more active and severe disease, as evidenced by higher levels of C-reactive protein (CRP) and anti-dsDNA, reduced complement C3 and C4, and a higher frequency of renal and neurological complications (P < 0.05).ConclusionOur data suggest that promoter variation in TLR9, specifically the rs5743836 C allele and the combined rs187084-rs5743836 CC haplotype, is linked to an increased risk of SLE and more disease activity and severe clinical presentation.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"1030-1039"},"PeriodicalIF":1.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148150281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A structured primary care-led triage and referral pathway for systemic lupus erythematosus: Operational criteria and referral outcomes from a real-world rheumatology practice.","authors":"Juan Sebastián Therán, Andrés Felipe Otero Rueda","doi":"10.1177/09612033261484768","DOIUrl":"https://doi.org/10.1177/09612033261484768","url":null,"abstract":"<p><p>ObjectiveTo describe the operational criteria and characterize the referral outcomes of a structured primary care-led clinical triage pathway for systemic lupus erythematosus (SLE), implemented by a family physician with postgraduate training in rheumatology.MethodsWe conducted a retrospective observational study including 148 adult patients with confirmed SLE managed between January 2025 and January 2026 at SERVIMED IPS, Colombia. The structured triage pathway was in active clinical use throughout the study period. For the purposes of this analysis, patients were classified into a four-level triage framework with predefined clinical and laboratory criteria for each management tier (continued primary care, programmed referral, prioritized referral, and urgent referral) by applying those criteria retrospectively to documented clinical and laboratory records. Primary outcomes included time to rheumatology assessment and indications for referral.ResultsOf 148 patients (84.5% female; median age 38 years), 93 (62.8%) required rheumatology consultation (38 programmed, 55 prioritized) and 19 (12.8%) required urgent referral. Median time to rheumatology assessment was 22 days (IQR 15-31) for prioritized and 49 days (IQR 38-62) for programmed referrals. Urgent referrals were evaluated within a median of 2 days (IQR 1-3). Newly diagnosed patients were more frequently classified at Level 3 than established patients (56.5% vs 28.4%). Triage reclassification occurred in a minority of cases. SLEDAI-2K was available in 92 patients (median 6, IQR 4-10).ConclusionsA structured primary care-led triage pathway with explicit operational criteria provides a descriptive framework for risk-stratified referral to rheumatology care for patients with SLE in resource-constrained settings. The observed referral times are preliminary descriptive findings that warrant prospective comparative evaluation. Formal inter-rater reliability assessment and independent validation studies are needed before broader implementation recommendations can be made.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"9612033261484768"},"PeriodicalIF":1.8,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uncertainty in illness and psychological adjustment in patients with systemic lupus erythematosus.","authors":"Theresa A Skojec, Tatiana M Davidson, Teresa J Kelechi","doi":"10.1177/09612033261484790","DOIUrl":"https://doi.org/10.1177/09612033261484790","url":null,"abstract":"<p><p>Systemic Lupus Erythematosus (SLE) is a chronic illness characterized by unpredictability, which increases the risk of experiencing uncertainty in illness. The literature suggests that uncertainty in illness decreases psychological adjustment to illness in several chronic conditions. The purpose of this cross-sectional descriptive study was to explore the relationship between uncertainty in illness and psychological adjustment to illness in individuals diagnosed with SLE. Patients with a diagnosis of SLE were invited to complete an anonymous battery of online questionnaires assessing uncertainty in illness, psychological adjustment, quality of life, and social determinants of health factors. Uncertainty in illness was found to be positively correlated with depression and anxiety. These findings suggest that uncertainty in illness increases the risk of experiencing symptoms related to anxiety and depression among individuals diagnosed with SLE. Further, it is crucial that individuals diagnosed with SLE receive regular screening for symptoms related to depression and anxiety.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"9612033261484790"},"PeriodicalIF":1.8,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148813394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}